Levosimendan Improves Hemodynamics and Exercise Tolerance in PH-HFpEF is a research paper published in JACC Heart Failure (2021). On theSindex it has a DataRank of 2.4. It has been cited 79 times, with 53 citing works in its 1-hop citation network.
Scored on demand from live citation data
Repositories this paper deposited data in (declared in PubMed).
DataRank reads this dataset's downstream impact straight off the citation graph â no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full â never from an abstract alone.
Base Score Contribution
0.657
From this paper's citation signal
Citation Network Contribution
1.7
From 38 citing papers with measurable signal
Ranked by each citer's contribution to N(p) â log1p(Cq) divided by its reference count â out of 53 citers.
AstraZeneca
Grant: R01 HL140731
AstraZeneca
Grant: R01 HL149423
AstraZeneca
Grant: R01 HL107577
AstraZeneca
Grant: R01 HL127028
American Heart Association
Grant: 16SFRN28780016
American Heart Association
Grant: GPSGC24800006
United Therapeutics Corporation
Grant: R01 LM01
United Therapeutics Corporation
Grant: P01 HL108797
United Therapeutics Corporation
Grant: FK506
United Therapeutics Corporation
Grant: R01 HL134905
National Institutes of Health
Grant: R01 HL128526
National Institutes of Health
Grant: U01 HL125205
Novartis
Grant: R01HL151841
Novartis
Grant: 1R01HL131029
NHLBI NIH HHS
Grant: P01 HL103455
NHLBI NIH HHS
Grant: R01 HL131029
Bristol-Myers Squibb
Eisai
Abbott Laboratories
Novo Nordisk
Amgen
Boehringer Ingelheim
Cardiovascular Medical Research and Education Fund
Cytokinetics
Bayer Fund
Merck
Actelion Pharmaceuticals
Impulse Dynamics
Pfizer
GlaxoSmithKline
Tenax Therapeutics
FWCI
7.31
Citation Percentile
1.0%
Citation Trend
Fields of Study
MeSH Terms
Keywords
Sustainable Development Goals